Peter G. Schultz

This study evaluates CMX990, a coronavirus Mpro inhibitor, showing broad antiviral activity against multiple coronaviruses and superior pharmacologic properties compared to existing inhibitors.

This paper describes the development of orally bioavailable SARS-CoV-2 protease inhibitors with a hydroxymethyl ketone warhead, showing improved potency and bioavailability compared to previous compounds.

This paper identifies a novel small molecule scaffold targeting KLHDC2 via high throughput screening and demonstrates its utility in degrading BRD4 using PROTACs.

The paper shows that natural selection in a synthetic yeast endosymbiont system leads to mutations that enhance bacterial coexistence within yeast.

The paper describes an orthogonal T7 replisome system in E. coli that enables continuous hypermutation of genes, leading to accelerated evolution of protein functions.

This paper identifies mCMQ069, a novel antimalarial with potential for single-dose cure and one-month chemoprevention, showing improved pharmacokinetic properties over KAF156.

This paper introduces CMX990, a potent SARS-CoV-2 3CL protease inhibitor with improved potency and clearance compared to nirmatrelvir, advancing to Phase 1 clinical trials.

This paper develops three prodrug formulations of atovaquone for long-acting injectable malaria chemoprotection, showing two maintain therapeutic plasma levels for over 70 and 30 days in monkeys.